flow trial semaglutide kidney outcomes 2024 nejm hazard ratio Long-term of in obesity and cardiovascular disease in the SELECT flow trial semaglutide kidney outcomes

The General Medical Council (GMC) and NICE guidance support patient-centred care that acknowledges real-world behaviours whilst prioritising safety and treatment efficacy

As hyperglycemia is a well-recognized contributor to the pathogenesis of diabetic encephalopathy through promoting oxidative stress, neuroinflammation, and insulin resistance, restoring blood glucose to near-normal levels is a critical therapeutic target 24,25

This has reinforced socio-spatial inequalities, reduced access to essential services, and fostered unsustainable transport reliance

By aligning patient biology with drug discovery, Phenomix is shaping a more personalized and impactful future for obesity treatment

Weight typically drops after menstruation begins